Aug 5 2015
Protea Biosciences Group, Inc. announced today that it has commenced shipments of a new, proprietary, silicon nanochip, known as REDIchip, that reduces the time to identify and quantify small molecules in biofluids. Initial shipments have been made to customers in North America, Europe and Asia.
Known as REDIchip™ ("Resonance-Enhanced Desorption Ionization"), the product employs a patented, "nanopost array" (NAPA) nanotechnology invented in the laboratory of Prof. Akos Vertes, PhD., Department of Chemistry, The George Washington University, and exclusively licensed to Protea.
"We are pleased to have commenced shipments of REDIchips to our customers. REDIchip greatly improves a researcher's ability to rapidly detect and quantify small molecules in biofluids, in a contaminant-free environment. REDIchip employs a highly organized, high density nanopost array design that produces 27 million nanoposts for each two millimeter spot," stated Steve Turner, Protea CEO. He added, "REDIchip provides exceptional sensitivity and reproducibility of results."
REDIchip technology was developed by Protea in conjunction with a $14 million DARPA cooperative research agreement led by The George Washington University and including GE Global Research and SRI International. The DARPA project goal is to develop new tools to elucidate the mechanism of action of a threat agent, drug, biologic or chemical on living cells within 30 days from exposure. Uncovering the mechanism of action of such agents in 30 days compared to the years currently required will enhance and support the development of effective threat countermeasures.
REDIchip is formatted as a disposable, single use, 96 spot target plate, suitable for simple and complex biological mixtures, and compatible with most standard MALDI-MS instrument systems.